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Abstract
The advancement of high throughput omic technologies during the past few years has made it
possible to perform many complex assays in a much shorter time than the traditional approaches.
The rapid accumulation and wide availability of omic data generated by these technologies offer
great opportunities to unravel disease mechanisms, but also presents significant challenges to
extract knowledge from such massive data and to evaluate the findings. To address these challenges, a number of pathway and network based approaches have been introduced. This review
article evaluates these methods and discusses their application in cancer biomarker discovery using
hepatocellular carcinoma (HCC) as an example.
Key words: Biological pathways, system biology, high-throughput omics data, cancer biomarker.

Introduction
A better understanding of disease associated
with biomarkers could potentially start a new area for
uncovering the mechanism of cancer progression,
development and offer better targets for drug development [1]. Studies on single gene/protein/
metabolite molecular signatures offer limited insight
into the complex interplay among the molecules responsible for progression of complex diseases such as
cancer. Thus, there is a shift toward the identification
of a panel of genes that interact directly or indirectly
in the form of pathway or complex network to evaluate their association to cancer [2,3]. This is accomplished through massive data derived by high
throughput omic technologies such as next generation
sequencing, microarray, and mass spectrometry.
Although thousands of candidate biomarkers have
been discovered by these technologies, few of them

have been transferred into practical application in
clinical setting and new drug production. The challenges lie in (1) high false positive rate of the candidate biomarkers identified from omics data; (2) Lack
of attention on the study of the context of biomarkers
who are interacting each other in the form of pathway
or network associated with cancer; (3) Fragmental and
incomplete information based on biomarkers identified from solely omics platform; (4) Lack of effective
algorithms that allow integration of diverse omics
data sources to simulate the biological pathway and
networks. To meet these challenges, a number of
pathway and network based approaches have been
introduced. This review article evaluates the advantages and limitations of these methods.
The traditional approaches that individual and a
panel of cancer biomarkers are selected by analytic
http://www.jcancer.org
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methods such as analysis of variance (ANOVA), Lasso, pairwise, information theory and support vector
machine (SVM) do not explicitly consider interaction
between genes, proteins and metabolites. Compared
to traditional methods, pathway and network centric
methods naturally provide a way to understand the
underlying pathways and the interactions between
individual signature markers and non-markers. With
the large-scale generation and integration of genomic,
transcriptomic, proteomic, and metabolomic data,
pathway/network-based methods provide a more
effective and accurate means for cancer biomarker
discovery. Increasingly, pathway and network-based
analyses are applied to omics data to gain more insight into the underlying biological function and
processes, such as cell signaling and metabolic pathways as well as gene regulatory networks [4-6]. A
number of pathway /network approaches have also
been used for improving the prediction of cancer
outcome, providing novel hypotheses for pathways
involved tumor progression [7], and exploring cancer
associated biomarkers [8]. For example, Taylor et al.
[9] combined gene expression data with physical
protein-protein interaction data to identify subnetwork markers for the prognosis of breast cancer and
lymphoma patients. Torkamani and Schork [10] used
gene co-expression network to infer cancer-initiating
genes in breast, colorectal cancer, and glioblastoma.
Kim et al. applied the MAPIT (Multi Analyte Pathway
Inference Tool) algorithm to identify prognostic network markers to predict GBM patient survival time
using multi-analyte network markers discovered by
integrating gene expression profile, epigenomic profile, and protein-protein interactome [11]. Goh et al.
[12] built a human disease network (HDN) by linking
hereditary disease that share a disease-causing gene
recorded in Mendelian Inheritance in Man (OMIM)
database. Although the functional connections in the
HDN remain to be further demonstrated, it inspires
us to systematically study the relationships among
diseases by constructing a network. More detailed
descriptions of relationships between human disease
and network essential for understanding of human
have been recently summarized in reviews [2, 12-14].
In this review, we provide some pathway and
network centric computational approaches and their
applications for biomarker discovery.

Summary of pathways and networks
centric approaches for cancer biomarker
discovery
Availability of biomedical pathways and networks based on large-scale data gathering through
diverse omics data sources offers new opportunities
to explain the causality of relationships between bio-
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logical entities and cancers [15]. As shown in Figure 1,
the general steps of the biomarker discovery include
the following: 1) Define precisely a well-framed, relevant clinical problem and focus the experimental
design around appropriate study populations and
samples; 2) Collect tissue samples or fluids from patients and suitable assays; 3) Acquire high-throughput
data from the omics technologies; 4) Analyze the data
using signal processing, statistical and machine
learning methods to select relevant features from the
data; 5) Integrate the pathway/network knowledge
from databases such as KEGG, HMDB and Reatcome
mapping candidate biomarkers to the corresponding
pathways or networks; 6) Evaluate biomarkers to estimate their diagnostic or prognostic capability and
clinical validity using alternative technologies such as
Westen blot, ELSA, and RT-PCR. In computational
aspect, cross-validation and independent validation
are the commonly used methods to evaluate the performance of a biomarkers. P-values, sensitivity, specificity and the area under receiver operating curves
(AUC) are used as quantitative indicators of the performance of the methods [16]; 7) Use the biomarkers
for clinical applications after reliable pre-clinical tests
and validation of the markers in a large population.

Statistics methods
Statistical methods test scientific theories when
observations, processes or boundary conditions are
subject to stochasticity. For examples, the classical
t-test has been extensively used for testing differential
gene expression in microarray data [35]. However,
this kind of procedure relies on reasonable estimates
of reproducibility or within-gene error, requiring a
large number of replicated arrays. Thus, several
methods for improving estimates of variability and
statistical tests of differential expression have been
proposed. For example, Significance Analysis of Microarrays (SAM) aimed to improve the unstable error
estimation in the two-sample t-test by adding a variance stabilization factor which minimizes the variance
variability across different intensity ranges [36, 37].
ANOVA model approach is widely used in multiple
kinds of omic data. For example, it was used to model
microarray data with the effects of array, condition,
and condition-array interaction and then to fit the
residuals with the effects of gene, gene-condition interaction, and gene-array interaction [38,39]. Also, it
was applied to capture the effects of controlled
groups, batches, condition, alias of experimental
equipment, and condition-metabolite interaction separately on LC-MS data [40]. To improve the accuracy
and sensitivity of analytic results, false discovery rate
(FDR) [41] and its refinement, q-value, (q-value
package, www.bioconductor.org) have been rapidly
http://www.jcancer.org
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adopted for genomic, proteomics and metabolic data
analysis including the widely-used SAM, DAVID [42]
and other approaches [36]. Another statistics method
for biomarker discovery is linear discriminant analysis (LDA), one of the classical statistical classification
techniques based on the multivariate normal distribution assumption, is quite robust and powerful to
discover biomarker or pathways between omics data
for many different applications despite the distributional assumption. Compared to LDA, quadratic discriminant analysis (QDA) requires more observations
to estimate each variance-covariance matrix for each
class [43]. In addition, logistic regression analysis has
been successfully used to evaluate biomarker performance of prostate cancer with mRNA profiling
[44]. Logistic regression (LR) model based on the regression fit on probabilistic odds between comparing
conditions requires no specific distribution assumption (e.g. Gaussian distribution) but is often found to
be less sensitive than other approaches[42,43].

edges have weights, and nodes and edges can be of
different types. Recent publications have applied
graphical modeling in computational biology to study
biological networks, enhance the ability to draw
causal inferences from functional MRI experiments,
support the early detection of disconnection and the
modeling of pathology spread in neurodegenerative
disease such as Alzheimer's disease [45-49]. For example, in mammalian cells, Bleris et al. have had early
success in characterizing the dynamics of key feed
forward modules and motifs, helping to enable the
circuit design of adaptive gene expression [50]. Using
graph based approaches, Ma'ayan et al. model cellular
machinery including genes, proteins and other subcellular compartments [51], in which the interactions
between components are drawn as edge connections
between the relevant nodes [51]. Gene expression data
combined with network analysis can yield important
information on how expression variation relates to
differences between observed states [52]. As closely
connected genes tend to be involved in similar functions, network annotation can complement clusters
obtained via fold change analysis [7]. A standard
systems-based approach to biomarker and drug target
discovery consists of placing putative or known biomarkers in the context of a network of biological
interactions, followed by different ‘guilt-byassociation’ analyses [53].

Graph theory based network and visualization
The modeling fundamentals of graph theory are
often used to describe the global topology, structure
or the community of a complex system. It emphasizes
on entities (e.g, genes, proteins, diseases, biological
process) and the relations between them. The complexity of graphical modeling can be either simple
only with nodes and edges or more complex where
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Figure 1. The pipeline
of pathway/networks
centric approach for
cancer
biomarker
discovery. A variety of
computational tools
and algorithms have
been proposed for
biomarker discovery
based on pathway and
network
methods.
The most commonly
used methods are
categorized roughly
into statistical [17],
graph theory [18],
Bayesian
methods
[19], text mining [20],
machine
learning
[21-23] and integrative
methods summarized
in Table 1.
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Table 1. Computational methods for biomarker discovery categorized by their application, examplary tools and URLs.
Approaches
Technique & Application Examples
Statistical anal- Hypothesis testing, random sampling. ANOVA. Detection of
ysis
differentially expressed genes/proteins, genotypes, biomarker
filtering/selection[24]
Pattern recognition

Machine learning, Probabilistic, instance-based, kernel classification models. Clustering, multi-source data classification,
biomarker selection and associations [25] Bayesian regression
models [26], partial least squares [27], and Genetic Algorithm/KNN [28].
Graph/network Network topology analysis, network visualization and data
theory
integration, clustering. Genetic, regulatory, protein-protein,
signaling network analysis, biomarker/target identification
[29]
Data visualiza- Sequence and cluster visualization, interactive visualization,
tion and imag- statistical analysis graphs. Data exploration, biomarker visualing
ization, model explanation, in vivo/in vitro imaging of molecules and cells [29]

Natural language processing and
information
retrieval
Software development,
Internet technologies

Exemplary Tools &URL
BRB:http://linus.nci.nih.gov/BRB-ArrayTools.html
PAM: http://www-stat.stanford.edu/~tibs/PAM/
SAM: http://www-stat.stanford.edu/~tibs/SAM/
Weka: http://weka.wikispaces.com/
LIBSVM: http://www.csie.ntu.edu.tw/~cjlin/libsvm/
PRTools: http://prtools.org/
R package: http://cran.r-project.org/web/views/Bayesian.html

BioNet[4]
:http://www.fda.gov/ScienceResearch/BioinformaticsTools/ucm285284.htm
Jung: http://jung.sourceforge.net/
http://bioinfo.mc.vanderbilt.edu/dmGWAS.html [30]
Cytoscape [31]: http://www.biotapestry.org/
Medusa: http://coot.embl.de/medusa/
Graphviz: http://www.graphviz.org/
Osprey:http://biodata.mshri.on.ca/osprey/servlet/Index
Pajek: http://vlado.fmf.uni-lj.si/pub/networks/pajek/
3Omics: http://3omics.cmdm.tw
Ontologies, text mining, information representation standards, iHOP: http://www.ihop-net.org/UniPub/iHOP
information retrieval and extraction. Inference of functional
CoPub: http://services.nbic.nl/copub/portal
associations from publications, automated annotation and
PolySearch: http://wishart.biology.ualberta.ca/polysearch/
characterization [32,33]
index.htm
Open Biomedical Annotator: http://bioportal.bioontology. org/annotator
GeneSeeker: http://www.cmbi.ru.nl/GeneSeeker/
Data warehouses and distributed information systems, seman- IPA:http://www.ingenuity.com/products/pathways_analysis.htm
tic Web tools, information retrieval, extraction and curation.
GO: http://www.geneontology.org/GO.tools.shtml
Biomarker discovery and validation platforms, data mining
MiMI: http://mimi.ncibi.org/MimiWeb/main-page.jsp
tools, search and reasoning engines [34]

The goal of visualization is to find patterns and
structures that remain hidden in the raw unstructured
datasets. Graph visualization is key to display directly
the various relationships between entities (e.g., genes,
proteins). Challenges of graph visualization lie in 1)
the high false positive rate of incorporating heterogeneous multi-omic datasets; 2) Visual representation
of the logical structure transformed from the raw data; 3) Graph manipulation and layout algorithm for
representing the complicated relationships between
biological entities. 4) Heterogeneous omic data from
different level visualization needs more flexibility for
layered representation. A number of commercial and
free sourced graph visualization tools and platforms
have been extensively developed. For example, Cytoscape [31], one of the free open source platforms
providing biological network analysis and visualization with more than 172 registered plugins contributed by the community, is very versatile in network
applications, such as network importing, network
integrating, inference customization, literature mining, topological clustering, functional enrichment,
network comparison, and programmatic access [54].
3DScapeCS,
a
Cytoscape
plugin
providing
three-dimensional, dynamic, parallel network visualization for Mass Spectrometry (MS) molecular network [55]. IPA [56], a commercial software tool for
pathway analysis with omics data provides powerful
graphical visualized pathways and networks overlaid
by diseases, drugs and biological process etc. Path-

wayStudio provide abstractive graphical interface for
users to analyze gene expression, protein interaction
and metabolic data to analyze and explore the pathways and networks identified from data. STRING not
only gives the graphical visualized protein interaction
of both known and predicted but also quantifies each
pair of proteins by their interaction types such as
physical interaction and gene fusion etc. [57].

Bayesian methods and its derivatives.
Bayesian methods allow informative priors so
that prior knowledge or results of a previous model
can be used to inform the current model. In cancer
bioinformatics and systems biology, the primary application of Bayesian methods include Bayesian inference, Bayesian network, Naive Bayes classifier and
Bayesian variable selection. Among these methods,
Bayesian network is one of the most common modeling tools for pathway and network analysis [19].
Bayesian network is a form of directed statistical
modeling designed to capture conditional dependencies between probabilistic events [58]. It consists of a
dependency structure and local probability model
also named probabilistic graph models which include
Hierarchical Bayesian Networks (HBN), Probabilistic
Boolean Networks (PBN), Hidden Markov Models
(HMM), and Markov Logic Networks (MLN) [59-61].
The dependency structure specifies how the variables
are related to each other by drawing directed edges
between the variables without creating directed cycles. Each variable depends on a possibly set of other
http://www.jcancer.org
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variables, termed "parents." Compared with other
pathway/network centric method, Bayesian network
model is capable of integrating heterogeneous data,
missing value and dependent relationships between
variables [62].
In a Bayesian network model, probabilities define the relationship between the current node and its
predecessor or parent in a graph [63]. The power of
these methods lies in their ability to facilitate the reverse engineering of multiplex networks based on
molecular expression, molecular activity and/or cell
behavior data, serving as a precursor to synthetic
modifications of existing molecular pathways
[64]. Bayesian inference is one of the very important
Bayesian methods widely used in cancer biomarker
discovery, signaling pathway and network inference
[65,66]. It has previously been applied to gene expression data for inference of gene regulatory networks [67,68], infer both protein signaling networks
[69,70] and gene regulatory networks [71]. To incorporate an explicit time element, dynamic Bayesian
Inference was proposed to interrogate dynamic signaling responses within a Bayesian framework, with
existing signaling biology incorporated through an
informative prior distribution on networks [66]. In
addition, Bayesian variable selection aims at solving
the problems of “large p, small n” existing in omic
data set and using prior knowledge such as pathway
and protein interaction to estimate the posterior
probability by Markov Chain Monte Carlo (MCMC)
also widely used to infer functional interactions in
biochemical pathway, model the interactions between
different functional modules of a biological network
[72] and pathway based cancer biomarker discovery
[73,74]. For example, Yang et al. [21] used a Bayesian
network to construct HCC cell networks and identify
functional modules and interactions between these
modules. Stochastic simulation models offer an alternative, but they are hitherto associated with a major disadvantage: their likelihood functions cannot be
calculated explicitly, and thus it is difficult to couple
them to well-established statistical theory such as
maximum likelihood and Bayesian statistics. A number of new methods, among them Approximate
Bayesian Computing and Pattern-Oriented Modeling,
bypass this limitation. The difference between Bayesian and frequentist inference lies in the following: 1)
Bayesian inference provides answers conditional on
the observed data and not based on the distribution of
estimators or test statistics over imaginary samples
not observed (Rossi et al., 2005, p. 4); 2) It includes
uncertainty in the probability model, yielding more
realistic predictions. 3) It safeguards against overfitting by integrating over model parameters. But the
quality of the prior information directly impacts the
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performance of the Bayesian methods. Also, they are
unable to account for feed- back regulation, a hallmark of signaling networks.

Text mining
With the growth of information in literature and
biomedical databases, biological and clinical scientists
need efficient means of handling and extracting diagnostic methods and prognostic terms and information from scientific literature. For this purpose, text
mining that comprises the discovery and extraction of
knowledge from free text to generate new hypotheses
particularly relevant and helpful in biomedical research [14]. Text mining complements the reading of
scientific literature by individual researchers, allows
rapid access to information contained in large volume
of documents and increases the reproducibility of
literature searches by enabling users to process all
documents for a specific result. The primary application of text-mining in biomedical research roughly lies
in three aspects: 1) Simple text-mining such as transforming textual information into database content and
integrating with existing knowledge resources to
suggest novel hypotheses; 2) Literature analysis including clustering and classification of entities or
diseases; 3) Integrative biology for producing or testing hypotheses against knowledge bases.
Currently, text mining is being successfully applied to the identification of molecular causes of diseases using facts from databases and literature [75-77].
For example, text-mining has been used to suggest
disease biomarkers from the scientific literature, and
made on the basis of the assumption that two proteins
are likely to interact with each other if they share a
substantial amount of contextual information [78,79].
By defining a gene of interest, a network is constructed from all scientific publications related to the
query-defined gene. The results can be browsed by
navigating through the visualized network. CoPub
makes uses of lexical resources for genes, proteins,
Gene Ontology labels, diseases, pathways, drugs and
tissues to identify and statistically to qualify the significance of a specific term for a gene or a set of genes
[80]. The results return a set of annotations for their
genes of interest. Besides, text mining has been widely
used in industrial large scale knowledge base for
query genes, proteins, metabolic compounds and
drugs functional analysis. To visualize knowledge
contained in the scientific literature, software tools
have been developed that provide improved integration of text-mining results with other data resources.
For example, IPA (Ingenuity) [56], KEGG [81], Pathway Studio [82] and HPRD [83] use text-mining to
integrate gene/protein-phenotype associations linking genes and protein variants to the diseases, toxic
http://www.jcancer.org
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effects and drug response to their knowledge databases.
Depending on the tasks researchers address,
text-mining can achieve different objectives. This include primarily the following: 1) retrieval information
from relevant documents; 2) Identification of entities
such as genes, diseases, complex relationship between
entities and diseases and interactions between proteins and genes [80]; 3) Deposit extracted information
into database or used to support manual database
curation efforts [15]; 4) Generation hypothesis [79]
and test novel research questions [78]. The trend of
text-mining technique is shifting from the analysis of
only abstracts to the full text of papers, from the
analysis of gene and protein-related information to
the information about cells, tissues and whole organisms. The most prominent shift is to integrate information from the literature with data sets from other
domains such as gene expression profiles [84], genome-wide association studies (GWASs), biochemistry and phenotype [84,85]. Text-mining is prone to
integration with machine learning, statistical techniques. In the future, text-mining might face several
major challenges such as improve literature analysis,
integrate to existing knowledge base, visualization of
extracted information.

Machine learning
Machine learning methods have been used for
the biomarker discovery from high-throughput omics
data, inferring causal relations between mutations
and diseases [21] , interactions between genes and
proteins [86-88] and relations between environmental
features and cancer [89] as well as pathway and network modeling. There are two kinds of basic machine
learning techniques, one is unsupervised machine
learning
such
as
hierarchical
clustering,
self-organizing mapping (SOM) etc. [90]. The other is
supervised machine learning which needs known
knowledge from data train a model and then apply
this model to predict the output variables [3]. A
number of machine learning such as SVM [14], Artificial Neural Network [91], decision tree and random
forests (RFs) etc. have been widely for various applications including identification of breast cancer biomarkers [92], diagnosis biomarker of Parkinson disorders [93], subcellular locations of proteins [94,95],
the prediction of protein functions on the basis of
protein structures [96,97], the annotation of mutations
[98,99]. For example, Han proposed a machine learning based derivative component analysis method to
select implicit feature by capturing subtle data behaviors and removing system noises from a proteomic
profile to overcome the reproducibility problem for
biomarker discovery in proteomics [100]. Another
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interesting study by Hoshida et al [101] combined
eight independent cohorts of gene expression profiles
to reveal the subclass of HCC and their related pathways using unsupervised machine learning methods.
They found that three common subclasses (S1-S3) of
hepatocellular carcinoma (HCC) were significantly
correlated to Wnt pathway, MYC, AKT and hepatocyte differentiation respectively. Westen blotting;
knockout and immunohistochemical staining were
used for experimental validation of their discovery.
Another framework called knowledge-driven matrix
factorization (KMF) proposed by Yang et al. was used
to reconstruct phenotype-specific modular gene networks [21].

Integrative methods
Integration of data from multiple omic studies
not only can help unravel the underlying molecular
mechanism of carcinogenesis but also identify the
signature of signaling pathway/networks characteristic for specific cancer types that can be used for diagnosis, prognosis and guidance for targeted therapy.
The methods described in Sections A-E have proven
useful
for
discovering
biomarkers
from
high-throughput omic data, analyzing protein-protein, protein-DNA, and kinase-substrate interactions, as well as for genetic interactions among
genes [102]. These efforts have yielded good results in
cancer biomarker discovery, protein interaction and
interaction between genotype and diseases [103].
However, current omic technologies provide only
limited fragmented reality of the biological functions
within cell or cancer mechanism. Separate analysis of
the data generated from each of these technologies is
limited to revealing only partial aberrant molecular
changes, because the interaction of multiple molecules
cannot be modeled by isolated analysis of genes,
proteins or metabolites. Furthermore, limitations such
as intrinsic high noise, incomplete data, small sample-size, bias have motivated the use of integrative
omic analysis and use of prior biological knowledge
and information bases, rather than as mere collections
of single large-scale omic studies [14, 34, 104]. However, integration of multiple disparate data types remains a significant challenge in systems biology research. Most recently, attempts at integration of multiple high-throughput omics data have concentrated
on capturing regulatory associations between genes
and proteins by comparing expression patterns across
multiple conditions [105-107], combining functional
characterization and quantitative evidence extracted
from different data sources of all levels of gene products, mRNA, proteins and metabolites, as well as their
interaction [108-110]. Some previous works [81,
111-113] in integrative analysis utilize pathways in the
http://www.jcancer.org
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form of connected routes through a graph-based representation of the metabolic network [114]. Other approaches focus on the functional module of protein
interaction network and analyze experimental data in
the context of pathways using multiple source omics
data [14,115,116]. We and others have developed advanced bioinformatics tools and algorithms to facilitate the integration of diverse data types [34, 110,
117-120].
Different biological types of data, such as sequences, protein structures and families, proteomics
data, ontologies, gene expression and other experimental data sets show a growing complexity produced by numerous heterogeneous application areas.
The integration of heterogeneous data is therefore
becoming more and more important. In order to gain
insights into the complexity and dynamics of biological systems, the information stored in these data repositories needs to be linked and combined in efficient ways.

Application of biomarker discovery in
HCC
Hepatocellular carcinoma (HCC) is the fifth most
common malignancy and the third leading cause of
cancer death in the world, with the five-year survival
rate approaching 7% [33]. Treatments of HCC include
surgical resection and transplantation, ablation and
transarterial chemoembolization, and systemic chemotherapy. Even so, no existing systemic chemotherapy
is effective for advanced HCC [121,122]. For example,
Lovet et al. [123] reported that targeted therapy with
sorafenib which inhibits multiple tyrosine kinase receptors (RAS/VEGFR) may prolong survival by about
three months. However, due to the redundancy and
compensation of the signaling network in HCC, a
significant reorganization of the signaling network
observed such as down regulation of tumor suppressors (p53 and CHK1 when XIAP silenced or p-RB
when CDK6 silenced) and upregulation of tumor
promoting proteins (ETS1 when XIAP silenced or
p-CREB when CDK6 silenced) may confer the growth
benefit for cancer cells [124]. This example suggests
providing pathways and network information may
improve the efficacy of systemic chemotherapy of
HCC. Chang et al [125] partitioned the complex oncogenic signaling networks into basic units, or functional modules, of signaling activity (e.g., a protein
phosphorylating another protein to activate its kinase
activity) and demonstrated that gene expression signatures based on these modules can predict the effectiveness of pathway-specific therapeutics [125]. Except for surgical resection/transplantation of early
stage HCC, the survival time is not significantly prolonged by any of these treatments. Added to pathway
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and network centric method making use of omics data
with systematic chemotherapy will benefit the development of newer therapeutic targets for HCC
treatment.
In recent years, computational methods for
models take more and more important roles in the
HCC investigations [114,126,127]. Some computer
systems have also been developed. For example,
Shannon et al. [128] developed a java based tool Gaggle by integrating diverse databases (e.g., KEGG, BioCyc, String) and software (e.g., Cytoscape, R ) to
simultaneously explore the experimental data (e.g.,
mRNA and protein abundance, protein-protein and
protein-DNA interactions), functional associations,
metabolic pathways (KEGG) and Pubmed abstracts.
Recently, Zheng et al [129] identified the molecular
events underlying the development of HCV induced
HCC by integrating gene expression profile and protein interaction data. To get the subnetworks, they
refined the network by removing a network component if the number of nodes is smaller than five. They
found four subnetworks called normal-cirrhosis, cirrhosis-dysplasia, dysplasia-early and early-advanced
HCC networks. From each of the sub networks they
identified functional modules and hub genes. By
comparing the pathways in each sub networks, they
observed changes of pathways and network activities.
Their findings were validated by literature. Even
though the types of omics data they used only include
gene expression and protein interactions, they provide a way to study the changes of network activities
by analysis of omic data. Zhang et al. used systematical method including partial least squares, literature
mining technique and with GeneGO Meta-Core to
discover the biomarkers of HCC with gene expression
as well as protein data. Based on these marker genes,
they constructed down regulated and up regulated
networks. In the former, they identified 10 up regulated hub genes (MAPK1, SP1, HDAC1, YY1, ABL1,
PTK2, SMAD2, NCOA3; CDC25A and NCOA2). They
identified 7 hub genes (FOS, ESR1, JUNB, EGFR,
SOCS3; FOLH1 and IGF1) in the latter. Partial least
squares were employed to construct a classifier with
these biomarkers. They used five-fold cross-validation
and two independent datasets to evaluate the performance of the classifier. Furthermore, they used
experimental immunohistochemistry and western
blot measurements to verify the marker genes predicted by the classifier. Their results show that the
network-based approach facilitates biomarker identification and improves classification accuracy [130].
Hollywod et al [131] identified driver genes which are
potent diagnosis markers and mechanism study of
HCC using t-statistic map (TM) and transcriptome
correlation map (TCM) approaches with integration
http://www.jcancer.org
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of DNA copy number measured by genomics CGH
array and gene expression. They found 50 driver
genes with significant prognostic relevance to HCC
key signaling pathways such as mTOR, AMPK, and
EGFR. siRNA-mediated knockdown experiments was
used to evaluate the functional significance of the 50
driver genes [131].
Even though collection of diverse omics data to
analyze the relationships between HCC phenotype
and biological entities within the cell has been proved
powerful enough, such integration is still fragmentary, incomplete and inadequate to reflect the whole
picture of the cancer information and development.
The amount of omics data from genomics, proteomics,
metabolomics and interactomics is increasing. In pace
with the explosion of omics data, a number of
open-access databases, containing comprehensive
gene, protein interaction, biological pathway and
network information, are being developed to provide
biologists with valuable tools for analyzing the data
from complex biological systems. These include IntAct, BioGRID, MINT, KEGG, PID, STRING and
REACTOME etc. all of which provide very useful
qualitative mappings of functional associations between key components in canonical pathways [14].
Table 2 summarizes primary data source and URLs
specific to HCC.
Table 2. Data sources and URLs for HCC databases.
Data sources
EHCO[132]
Onco.HCC[133]
HCVpro[134]
HCVdb[135]
Hepatitis Virus Database
(HVDB) [136]
Los Alamos National
Laboratory in the United
States[137]
LiverAtlas[138]
dbHCCvar[139]

URLs
http://ehco.iis.sinica.edu.tw/
http://oncodb.hcc.ibms.sinica.edu.tw/index.htm
http://cbrc.kaust.edu.sa/hcvpro/
http://euhcvdb.ibcp.fr/euHCVdb/
http://s2as02.genes.nig.ac.jp
http://hcv.lanl.gov

http://liveratlas.hupo.org.cn
http://GenetMed.fudan.edu.cn/dbHCCvar

Limitations of omics based biomarker
discovery
With wide applications of omics technique, more
accurate and ubiquitous biomarkers have been identified, but only few have been brought to clinical setting and many have proved to be irreproducible [140].
One of the concerns is that biomarkers identified suffer from low diagnostic specificity and sensitivity
which leads to current cancer biomarkers have not yet
made a major impact in reducing cancer burden. For
instance, serum alpha-fetoprotein (AFP) is the most
widely used biomarkers for detecting and monitoring
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of HCC, but the false negative rate with AFP levels
may be high as 40% for patients with early stage of
HCC, for advances patients, the AFP levels remain
small in 15%-30% of patients [141].
One of the important limitations is possible artifacts in conducing biological experiments such as instrument variability. Others include bias in sample
collection and sample handling which lead to cohort
differences. For example, Sreekumar et al. [142] reported sarcosine as a prostate cancer biomarker
through metabolomics analysis. However, subsequent
validation study done by Jentzmik et al. [143] concluded that the levels of sarcosine measured by
GC-MS could not differentiate malignant from nonmalignant tissue. Collestelli et al. reported no statistically significant difference between prostate cancer
and healthy controls in the sarcosine to creatinine
ratios and that the levels of sarcosine were about
11.7% higher in the healthy controls [144]. Another
important limitation relates to lack of computational
methods that can extract knowledge from omic data
involving substantial amount of noise, high dimensionality, missing values, etc.
Although the use of pathway and network-based
approaches and the integration of prior biological
knowledge with omic data are promising in addressing some of the computational challenges, they too
have some limitations as outlined below:
• mRNA levels and DNA alterations may not accurately reflect the corresponding protein levels
and fail to reveal changes in posttranscriptional
protein modulation (e.g., phosphorylation, acetylation, methylation, ubiquitination, etc.) or
protein degradation rates. Correlation of mRNA
with its associated protein expression can be
relatively low. The signaling network constructed using these approaches does not reflect
the dynamic signal flow in a spatial relationship.
Also, the genomic changes (mRNA level, SNP,
CNV, methylation) ultimately affect protein expression, activation and inactivation, which, in
turn, controls cellular behavior.
• Current proteomic technologies provide only
limited coverage of the proteome and more sensitive technologies are needed to identify and
quantitate low abundant proteins [145,146].
• Interpretation of pathway mapping results from
the fact that pathway annotations currently take
little consideration of tissue specificities of genes
or proteins in the pathway. This limits the tissue
and/or isoform specificity in pathway annotations. Thus, specific steps of a pathway may not
be actually active in tissues/cells from which the
omics data may be generated. In some cases, this
may occur because protein isoforms or splice
http://www.jcancer.org
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variants have been annotated as a protein class
or a canonical protein sequence, respectively, in
the pathway while they may be expressed differentially in different tissues/cells.
• Because biological pathways are inherently
complex and dynamic, pathway annotations in
different pathway databases vary significantly in
pathway models and in a number of other aspects, e.g., specific protein forms, dynamic complex formation, subcellular locations, and pathway cross talks.
Current computational methods thus need to
provide a solution to these issues including revealing
patterns within the data, modeling heterogeneity,
profiling of disease classes and subclasses, producing
a predictive of patients’ classification, etc.. Biomarker
discovery is now changing research away from identification of individual biomarkers to searching for
perturbed pathways and network activities.

Conclusion
Early detection of cancer improves survival and
enhances quality of life. An ideal marker would be
one that can be measured easily and reliably using an
assay with high sensitivity and specificity and undergo rigorous validation before they are introduced
into routine clinical care. Currently, the treatment of
most cancers is based on the tissue types and clinical
stages. This approach is often ineffective due to the
heterogeneity of the tumors. Pathway and network
based method have taken more important role in
analysis of high-throughput data. Pathway and network based methods provide a global and systematical way to explore the relationships between biomarkers and their interacting partners. Thus, future
work is likely to focus on using pathway and network
based methods for biomarker discovery.
It is our expectation that methods discussed
above will become a component in a shared infrastructure of biomedical resources that can be used by
researchers to identify and to retrieve the most relevant work, to formulate hypothesis, to find supporting and contradicting evidence for hypotheses, to integrate research results into a framework of whole
biological systems and to support the translation of
research results across domains and into clinical applications.
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